Vessi Medical Overview
Vessi Medical is developing a new approach in the treatment of urological tissue. The company treats superficial urological tissue using surface cryotherapy, utilizing extreme cold to freeze and destroy abnormal tissue. The Vessi Medical system consists of a stand-alone console and a disposable catheter which is inserted into the bladder in a manner similar to existing intravesical techniques. Vessi's minimally invasive unique cryotherapy solution provides a therapeutic alternative to surgery while reducing the cost and complications associated with current treatments. First in human study (FIH) clinical trial was finalized (2023) , with very promising results.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Vessi Medical Closes $16.5 Million Series A Round for Innovative Cryotherapy Bladder Cancer Treatment
Vessi Medical Ltd. has raised $16.5 million in a Series A financing round for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer. The round was led by an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline, a trust of which UK investor Vincent Tchenguiz is a discretionary beneficiary. The funds will be used to expand Vessis R&D capabilities, conduct clinical studies in Israel and the U.S., and achieve regulatory clearance. The companys minimally invasive solution provides a new therapeutic alternative to the costly leading invasive surgical first-line therapy.
InvestmentExpand
growth-positive
Vessi Medical completes $1.7 million in funding for minimally invasive bladder cancer treatment
Israel-based medical device startup Vessi Medical has secured $1.7 million in funding for its cryoablation solution for superficial bladder cancer. The company plans to conduct its first-in-human study in Q1 2021 to demonstrate the safety and efficacy of its Vessi intravesical cryotherapy device. Vessi Medical aims to replace existing surgical treatments with its bladder-specific cryotherapy technology, which can be used in outpatient clinic treatment. The funding round included participation from Agriline, The Trendlines Group, the Israel Innovation Authority, and ExitValley Investors. The companys progress in product development and ability to secure funding during the COVID-19 pandemic was praised. Vessi Medical was founded in 2015 and operates in northern Israel.
Investment
growth-positive
Freezing out tumors may offer relief in bladder cancer
Vessi Medical, a startup incubated by the Trendlines Group, aims to reduce the rate of recurrence of non-muscle invasive bladder cancers (NMIBC) through cryoablation. Cryoablation uses extreme cold to destroy tissue and has been used for other types of cancer but never for NMIBC. Vessi Medicals cryotherapy is delivered as a spray to minimize physical contact with the bladder mucosa and reduce the risk of spreading cancer cells. The company is seeking $1-3 million in funding to begin clinical studies on humans and obtain FDA approval. NMIBC affects 2 million people globally, and Vessi Medicals initial market is estimated at $1.2 billion. If successful, commercialization could begin by the end of 2022.
Customers
growth-positive
Vessi Medical developing new treatment for superficial bladder cancer - BioTuesdays
Vessi Medical, a medical technology company, aims to revolutionize the treatment of superficial bladder cancer with its surface cryotherapy approach. The companys technology involves freezing the tumor to ablate it, eliminating the risk of dispersed cancer cells without damaging bladder functionality. Vessi is targeting a $1.2 billion market opportunity to treat non-muscle invasive bladder cancer. The company plans to conduct first-in-human trials in late 2019 or early 2020. Vessi is seeking up to $3 million in financing for its trials and regulatory submission process. The company plans to seek regulatory approvals and start commercialization in 2022. Vessis technology could also have applications in treating recurrent urinary tract infections, overactive bladder, and upper urinary tract carcinoma.
Customers
growth-positive
Israeli startup seeks to freeze bladder tumors after seeing success in pigs
Israeli medical startup Vessi Medical Ltd. has developed a medical device for freezing tumors and treating superficial bladder cancers. The company has successfully concluded its first animal trials and is now seeking $1 million to $3 million in funding to begin human trials. Vessi Medicals bladder-specific cryotherapy technology aims to provide a less invasive alternative to current treatments for non-muscle invasive bladder cancer. The companys patent-pending cryotherapy system has a potential market target of $1.2 billion. The device can be inserted transurethrally into the bladder and uses a cryo-spray designed for the unique environment of the bladder. The funding for the research has been provided by The Trendlines Group, an Israeli incubator.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.2M |
| Last funding | $16.5M |
| Stage | A |
| Rounds | 2 |
| Investors | 6 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | www.vessimed.com |
Locations
Misgav, Israel
Photos & Videos
1 item(s)
